Continuing the tradition of immediate insight into how new data presented at ASCO 2014 is impacting clinical practice worldwide, MDoutlook has released its second of three OncoPoll™ report from ASCO 2014, focusing on Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma.
- CLL-treatment naïve is the largest proportion of lymphoma patients seen in clinical practices; Mantle cell lymphoma patients are the second most seen per quarter
- Results of the RESONATE trial are not expected to increase the usage of Ibrutinib for CLL- treatment naïve, CLL-relapsed/refractory, Del 17p or Del 11q patients (±0.3-2.2% change), in comparison to usage in the last three months
- The highest proportion of oncologists (39%) believe that GS-9973 will have a large impact to a minority of their relapsed/refractory CLL patients
- Oncologists would expect to use VR-CAP in a higher proportion (42%) of their transplant-ineligible Mantle cell lymphoma patients in comparison to R-CHOP (36%)
Download your courtesy copy of the MDoutlook ASCO 2014 OncoPoll – CLL report by clicking on the link.
MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research with all our colleagues.
MDoutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDoutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.
Please contact us discuss how MDoutlook can answer your disease intelligence needs.